Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial
William JH Mcbride, Walter P Abhayaratna, Ian Barr, Robert Booy, Jonathan Carapetis, Simon Carson, Ferdinandus De Looze, Rod Ellis-Pegler, Leon Heron, Jeff Karraschi, Helen Marshall, Jodie Mcvernon, Terry Nolan, William Rawlinson, Jim Reid, Peter Richmond, Sepehr Shakib, Russell L Basser, Gunter F Hartel, Michael H Lai Show all
VACCINE | ELSEVIER SCI LTD | Published : 2016
BACKGROUND: Before pandemic H1N1 vaccines were available, the potential benefit of existing seasonal trivalent inactivated influenza vaccines (IIV3s) against influenza due to the 2009 pandemic H1N1 influenza strain was investigated, with conflicting results. This study assessed the efficacy of seasonal IIV3s against influenza due to 2008 and 2009 seasonal influenza strains and against the 2009 pandemic H1N1 strain. METHODS: This observer-blind, randomized, placebo-controlled study enrolled adults aged 18-64years during 2008 and 2009 in Australia and New Zealand. Participants were randomized 2:1 to receive IIV3 or placebo. The primary objective was to demonstrate the efficacy of IIV3 against ..View full abstract
This study was sponsored by CSL Limited, manufacturer of Fluvax (R). Editorial assistance was provided by Justine South by, PhD, CMPP, and Luke Carey, PhD, of ProScribe - Envision Pharma Group, and was funded by CSL Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3).